Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

invasive breast cancer
cancer
breast cancer
adjuvant therapy
  • 33 views
  • 09 Jul, 2022
  • 6 locations
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects (CREATE)

Doxorubicin and epirubicin are part of the class of chemotherapy agents called anthracyclines that are commonly used to treat breast cancer. Although these treatments work well against the tumor

breast cancer
breast cancer staging
anthracyclines
cancer
doxorubicin
  • 143 views
  • 04 Oct, 2022
  • 1 location
Remote Ischemic Conditioning in Oncology (RICO)

This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements will be approached to participate in the study. The purpose of the study is to determine if performing remote ischemic …

  • 0 views
  • 11 Jul, 2022
  • 1 location
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity …

  • 14 views
  • 04 Oct, 2022
  • 1 location
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination …

  • 0 views
  • 04 Oct, 2022
  • 2 locations
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE)

(RIPC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines.

  • 0 views
  • 04 Oct, 2022
  • 4 locations
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in

carboplatin
mastectomy
sentinel node
paclitaxel
invasive breast cancer
  • 126 views
  • 23 Jan, 2021
  • 12 locations
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy

failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an

anthracyclines
primary cancer
treatment regimen
  • 0 views
  • 08 Oct, 2021
  • 1 location
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

with very limited mature B-NHL (R1 and R2 stage I and II) of substituting anthracyclines by the rituximab window without compromising survival rates. the effectiveness (event-free survival

  • 539 views
  • 16 Jun, 2021
  • 93 locations
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (CITRINE)

This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.

carboplatin
platelet count
breast cancer
triple negative breast cancer
paclitaxel
  • 28 views
  • 28 Feb, 2022
  • 1 location